The incidence of Barrett's esophagus (BE)-associated esophageal adenocarcinoma (EAC) is increasing. Next-generation sequencing (NGS) provides an unprecedented opportunity to uncover genomic alterations during BE pathogenesis and progression to EAC, but treatment-naive surgical specimens are scarce. The objective of this study was to establish the feasibility of using widely available endoscopic mucosal biopsies for successful NGS, using samples obtained from a BE 'progressor'. Paired-end whole-genome NGS was performed on the Illumina platform using libraries generated from mucosal biopsies of normal squamous epithelium (NSE), BE and EAC obtained from a patient who progressed to adenocarcinoma during endoscopic surveillance. Selective validation studies, including Sanger sequencing, immunohistochemistry and functional assays, were performed to confirm the NGS findings. NGS identified somatic nonsense mutations of AT-rich interactive domain 1A (SWI like) (ARID1A) and PPIE and an additional 37 missense mutations in BE and/or EAC, which were confirmed by Sanger sequencing. ARID1A mutations were detected in 15% (3/20) highgrade dysplasia (HGD)/EAC patients. Immunohistochemistry performed on an independent archival cohort demonstrated ARID1A protein loss in 0% (0/76), 4.9% (2/40), 14.3% (4/28), 16.0% (8/50) and 12.2% (12/98) of NSE, BE, low-grade dysplasia, HGD and EAC tissues, respectively, and was inversely associated with nuclear p53 accumulation (P ¼ 0.028). Enhanced cell growth, proliferation and invasion were observed on ARID1A knockdown in EAC cells. In addition, genes downstream of ARID1A that potentially contribute to the ARID1A knockdown phenotype were identified. Our studies establish the feasibility of using mucosal biopsies for NGS, which should enable the comparative analysis of larger 'progressor' versus 'non-progressor' cohorts. Further, we identify ARID1A as a novel tumor-suppressor gene in BE pathogenesis, reiterating the importance of aberrant chromatin in the metaplasiadysplasia sequence.
INTRODUCTION
Esophageal cancer represents the seventh most frequent cancerrelated cause of death in the United States. 1 The incidence of esophageal adenocarcinoma (EAC) has dramatically increased over the past decades. EAC arises from non-dysplastic Barrett's esophagus (BE) following a multistep progression through lowgrade dysplasia (LGD) and high-grade dysplasia (HGD), culminating in invasive neoplasia.
2 BE is found in 1.6-6.8% of the general population, and risk factors include presence of gastrointestinal reflux disease, Caucasian race, male gender, obesity and smoking. 3 The annual risk of developing HGD or EAC is 0.26-0.77% among BE patients. 4, 5 One of the hallmarks of carcinomas like EAC is the accumulation of genetic abnormalities that mirror histological progression from dysplasia to cancer. 6, 7 Prior studies have profiled global abnormalities of promoter methylation, transcriptomic aberrations and copy number alterations in the multistep progression of BE to EAC. [8] [9] [10] [11] [12] [13] [14] For instance, hypermethylation of the promoter regions of CDKN2A, RUNX3, HPP1, APC, TIMP-3 and TERT, deletions on chromosome 9p and 17p, abnormalities in DNA content, and presence of CDKN2A and TP53 mutations may have some promise as predictors of EAC development. 2, [15] [16] [17] [18] Remarkably, besides the relatively high prevalence of CDKN2A/p16 and TP53 mutations during EAC development, [16] [17] [18] there is still little known about the genetic landscapes of BE and EAC. It is of particular interest to discover whether subsets of somatic mutations observed in EAC are already present in BE and if such mutations might segregate patients most likely to progress to HGD or EAC ('progressors'), from the overwhelming majority who will never do. The identification of 'progressor' mutations would not only serve as a biomarker for patient stratification, but also as potential 'actionable' mutations that might block progression.
The availability of next-generation sequencing (NGS) technologies has enabled interrogation of the genomes of human cancers at an unprecedented scale. [19] [20] [21] [22] Nearly all of the previously published NGS studies have been restricted to invasive cancers, using either cell lines, xenografts or surgically resected carcinomas. 20, 23, 24 The application of NGS to microscopic precursor lesions is still in its infancy, although targeted capture and NGS of larger precursor lesions has now been shown to be feasible. 25 One of the challenges in the context of BE and EAC remains the availability of treatment-naive surgical resection samples, as many patients with EAC receive neoadjuvant chemo-radiation therapy, or locally ablative treatments in the pre-operative period. 26, 27 In contrast, endoscopic mucosal biopsies are widely available and readily banked by gastroenterologists as a component of endoscopic surveillance and/or clinical trials. Even in instances when endoscopic biopsies are obtained from patients who later develop advanced, surgically unresectable cancers, the pre-cancerous sample serves as an invaluable substrate for identifying potential 'progressor' mutations. We have previously demonstrated the utility of archived snap-frozen biopsies for generating the transcriptomic profiles of BE and EAC using serial analysis of gene expression, as well as for generating genomewide copy number and methylome profiles using array-based approaches. 10, 28 In this study, we utilized endoscopic mucosal biopsies obtained from an EAC patient to generate the first genome-wide profiles of BE and EAC. Our study fulfills two important objectives of significance vis-à-vis BE pathogenesis and progression: first, from a technological standpoint, it establishes the feasibility of using endoscopic biopsies for successfully performing genomic profiling of BE, which should facilitate future studies, such as comparing the landscapes of 'progressors' versus 'non-progressors'. Second, our study identifies the AT-rich interactive domain 1A (SWI like) (ARID1A) gene as a novel tumor suppressor in BE. The protein encoded by ARID1A is a key component of the highly conserved switch/sucrose non-fermentable chromatin remodeling complex. 29 Using sequencing and immunohistochemical studies on archival specimens and functional assays in cell lines, we establish the frequency of ARID1A mutations and ARID1A loss in the multistep progression of EAC, and the consequences of inactivating gene function on the neoplastic phenotype. Finally, we determine the downstream effectors of ARID1A that are likely to contribute to the oncogenic phenotype caused by ARID1A downregulation.
RESULTS
Whole-genome NGS was performed on normal squamous epithelium (NSE) (germ line control), BE and EAC tissues obtained from one individual during upper endoscopy. Single-nucleotide variants (SNVs) were identified using the Genome Analyzer Toolkit (GATK) and categorized into four tiers, as described by Mardis et al.
30 Table 1 contains SNVs in coding regions of annotated exons and splice sites (tier 1), and these variants have been validated by Sanger sequencing. SNVs in regulatory regions (tier 2), in non-repeat masked, non-regulatory regions (tier 3) and all remaining SNVs are listed in Supplementary Tables S1-S3, respectively. Among the validated tier 1 SNVs, 2 were called with low and 38 with high confidence by GATK. In addition, several tier 2/3/4 SNVs were validated by Sanger sequencing.
SNVs in coding regions of annotated exons and splice sites (tier 1) A total of 40 tier 1 SNVs were detected by NGS and confirmed by Sanger sequencing (Table 1) . Among these, 37 caused a functional amino-acid change (missense), 1 impacted the 5 0 splice site and 2 were nonsense mutations. The nonsense mutations were both present in genes located on chromosome 1p, in the coding regions of ARID1A and PPIE, and were detected in BE and EAC. Among the missense SNVs were monoallelic mutations of TP53, TFAP4 and ITGB3. Interestingly, the overwhelming majority of the tier 1 SNVs were found in both BE and EAC.
Many somatically altered genes in which we have found SNVs have either a direct or indirect interaction with a cancer pathway ( Figure 1 ). Four mutated genes, ARID1A, ITGB3, TP53 and TFAP4 are among the most connected genes in this network. Other important tier 1 genes include transcription regulators (IGF2BP2, LBX2) and G-protein coupled receptors (TASR1, GPR98). The known tier 1 gene functions in cancer development and/or progression are listed in Supplementary Table S4. ARID1A is mutated in a subset of HGD/EAC samples In addition to biopsies from our index patient, 14 frozen HGD/EAC and matched NSE biopsy samples, and 5 formalin-fixed paraffinembedded EAC and matched tumor-negative lymph nodes (control) tissues were subjected to mutational analysis of ARID1A using Sanger sequencing. In total, one nonsense mutation (g.27056230C4A (index patient)), and two indel mutations (g.27099353_27099354delCCinsAA and g.27023892delC) were detected in 20 patients (3/20 ¼ 15%). Both indel mutations resulted in the reading of a premature stop codon.
ARID1A protein loss occurs early in the EAC carcinogenesis ARID1A protein expression was examined by immunohistochemistry in an independent cohort of 98 EAC patients ( Figure 2 ). Nuclear staining patterns were categorized into two groups; present and lost expression. In some lesions exhibiting ARID1A loss, the loss was only observed in one clone of the lesion. ARID1A loss was observed in at least one lesion of fourteen EAC patients (14/98, 14.3%). Detailed information regarding in which lesion(s) of these patients ARID1A loss occurred is given in Figure 3a . Overall, ARID1A loss occurred in 0% (0/76), 4.9% (2/40), 14.3% (4/28), 16 .0% (8/50), 12.2% (12/98) and 6.5% (2/31) of NSE, BE, LGD, HGD, EAC and lymph node metastasis tissues, respectively (Figure 3b ).
Nuclear accumulation of p53 is significantly less common in the presence of concomitant ARID1A loss The distribution of age at diagnosis, gender and race were not statistically significant different between ARID1A-negative and -positive cases. ARID1A-negative cases lived by average 3.7 months longer (P ¼ 0.608). No correlations between ARID1A status and tumor features were found (Supplementary Table S5 ).
As it has been suggested that mutations in ARID1A and TP53 are mutually exclusive in cancer, and that the former might substitute for loss of p53 function, 31, 32 we examined the status of p53 in our cohort, using nuclear accumulation as readout for genetic abnormality (Figures 2 and 3c) . We observed that specimens with ARID1A loss demonstrated significantly less frequent nuclear p53 accumulation (P ¼ 0.028, Supplementary (Figure 3a ).
ARID1A regulates cell growth/proliferation and invasion of EAC cells ARID1A was knocked down (ARID1A KD) in OE33 cells by transfecting ARID1A small interfering RNA into the cells, and knockdown efficiencies of 75% and 81% at mRNA and protein level, respectively, were confirmed (Figures 4a and f) . Direct visualization of ARID1A KD in OE33 cells was established by immunocytochemistry (Supplementary Figure S1D , E). Loss of ARID1A was associated with significantly increased cell growth (Po0.001; Figure 4b ). This increased growth potential was validated by a 5-bromo-2-deoxyuridine (BrdU) proliferation assay, which confirmed significantly increased proliferation as the underlying mechanism (Po0.001; Figures 4d and e, Supplementary Figure S1C) . No significant differences in migratory Figure S2 , Supplementary Table S6 ). As we had observed a phenotype of significantly increased cell growth, proliferation and invasion on ARID1A loss in OE33 cells, we queried publicly available databases of gene function to identify putative candidate genes that have the ability to control these cellular processes. We selected 16 coding genes, which met these criteria; HPDG, CYP1B1, FGFBP1, S100A4, CEACAM5, PIM1, ACPP, BIRC3, CDKN1C and NRG1 were upregulated in ARID1A KD OE33 cells, whereas MT2A, SDHD, ATG5, RSG16, GSPT1 and RHOB were downregulated (Supplementary Figure S2 , Supplementary Table  S7 ). Expression levels of these genes were validated by quantitative reverse transcriptase-PCR in four biological replicate experiments. Specifically, transcripts corresponding to HPGD, MT2A, CYP1B1, SDHD, FGFBP1, S100A4, CEACAM5, ACPP, ATG5, RSG16 and NRG1 were statistically significant aberrantly expressed in ARID1A KD (Figure 4f , Supplementary Table S7 ).
DISCUSSION
In this study, we show that it is feasible to perform high depth NGS on snap-frozen endoscopic mucosal biopsies. To the best of our knowledge, this is the first example of whole-genome sequencing of matched precursor and invasive carcinoma obtained from a single patient. We found that the mutational profiles of BE and EAC in our NGS patient are remarkably similar, suggesting that genetic alterations in the metaplasia-carcinoma sequence of BE might occur much earlier than the histological changes of frank dysplasia. Consistent with this, Wang et al. 33 have previously shown that the transcriptomic profiles of BE and EAC are comparable, and our own group has shown that global hypomethylation observed in EAC actually occurs at the stage of BE itself. 10 Future studies utilizing NGS on endoscopic mucosal biopsies of progressors versus non-progressors should enable us to compare the genetic landscapes of these two BE groups.
Phenotypic heterogeneity of precursor lesions and cancers, and in particular the lack of sensitive sequencing techniques that are capable of detecting genetic aberrations in subclones of neoplastic cells, have delayed the development of accurate risk stratification tools for BE. The 'cancer stem cell' hypothesis and genetic heterogeneity potentially underlie phenotypic heterogeneity. [34] [35] [36] Studies have shown that only sub-populations of cancer cells, so-called 'cancer stem cells', have unlimited proliferative and clonogenic potential, and that these cells are most likely to initiate metastases formation. 35 Genetic heterogeneity is not limited to cancers from different cell origin and anatomic sites, but is also seen among patients with a particular cancer type, and even within individual tumors. 34, 36 Many solid cancers exhibit multiple subclones, and although these 
clones probably have the same driver mutations, they undergo clonal evolution acquiring additional (epi)genetic aberrations. 36 The expansion of the most dominant subclone, as shown in breast cancer, is likely to result in clinical symptoms and finally diagnosis. 37 However, as a consequence of ongoing lineage formation and branching, each subclone individually may be capable of initiating metastasis formation. 34, 36 NGS might enable us to detect alterations in subclones of BE and EAC that are specific to neoplastic and metastatic clones, respectively, and may result into risk stratification tools and drug discoveries.
In terms of the specifics of our genomic analysis, we observed somatic nonsense mutations of PPIE and ARID1A, both located on chromosome 1p. Inactivating mutations in ARID1A have been detected in several solid cancers including digestive tract cancers (Table 2 , summary of ARID1A mutations in solid carcinomas). 20, 38, 39 However, ARID1A mutations had not been reported in EAC till recently; while our manuscript was under review, a NGS study reported a nonsense mutation in ARID1A in 1 out of the 11 EAC patients (a summary of frequent exomic mutations identified in this and our NGS study is provided in Table 3) . 40 We detected an ARID1A nonsense mutation in our index patient, as well as indel mutations in two additional patients, suggesting that the mutational rate of ARID1A in EAC is B15% (3/20).
We further found that ARID1A loss occurs in 14.3% (14/98) of the EAC patients. We examined several stages of the metaplasiacarcinoma sequence in these patients and concluded that ARID1A is lost early in the carcinogenesis of EAC. As studies have reported that ARID1A mutations are negatively associated with TP53 mutations, 31, 32, 41 we determined the p53 status in our BE progression cohort. We observed that specimens with ARID1A loss demonstrated significantly less frequent nuclear accumulation of p53. The fact that our index patient harbored mutations in both ARID1A and TP53, also suggest that mutations in these genes are not always mutually exclusive.
Our in vitro studies suggested that ARID1A has an important role in the regulation of cell growth and invasion, which implicates ARID1A is a tumor-suppressor gene in EAC. Proliferation assays performed in four gastric adenocarcinoma cell lines by Zang et al. 41 , also indicated that ARID1A has the capacity to inhibit cell proliferation in the stomach. Global expression profiling identified novel downstream genes of ARID1A, which are all involved in regulating cell proliferation, survival and/or invasion. Among the upregulated genes in ARID1A KD OE33 cells are CYP1B1, S100A4 and CEACAM5. CYP1B1 is overexpressed in multiple carcinomas, and has an important role in tumor formation. 42, 43 In vitro experiments performed by Martinez et al. 44 suggest that CYP1B1 expression is correlated with docetaxel-resistance and increased cell survival in breast cancer cells. 43, 44 S100A4 is a member of the S100 family of calcium-binding proteins, and S100A4 upregulation leads to enhanced cell proliferation. It furthermore regulates cell cycle progression, apoptosis, and promotes tumor invasion and metastases formation. 45 ,46 S100A4 overexpression has been determined in 67% of the EACs, and was associated with the presence of lymph node metastases. 47 The third significantly upregulated gene is CEACAM5, better known as CEA, and is commonly used as a serum marker for colorectal adenocarcinomas. CEACAM5 is upregulated in nearly all colorectal adenocarcinomas, and 60% and 4.6% of the EAC and BE tissues, respectively. 48, 49 It has been extensively studied in vitro, and among others inhibits cell differentiation and anoikis.
50,51
PPIE mutations have not been reported before in EAC. Functionally, PPIE has been shown to directly bind to the third PHD finger of mixed lineage leukemia 1 (MLL1), which results into a switch in MLL1 function from transcriptional activator to repressor. 52 Overexpression of PPIE results in repression of oncogenic homeobox (HOX) gene expression, 52 ,53 whereas mutant PPIE is not able to bind to MLL1 and downregulate HOX genes. 53 In addition, PPIE is capable of downregulating the MLL1 target genes CDKN1B and C-MYC. 54 A nonsense mutation in PPIE combined with deletion or epigenetic silencing of the second allele would be postulated to cause complete inactivation of PPIE, leading to a dysfunctional switch between activation and repression of MLL1 target genes, which might promote cancer formation and/or progression.
In conclusion, our studies established the feasibility of using widely available and banked endoscopic biopsies for NGS, which should facilitate similar studies in larger cohorts of samples. Furthermore, we identified ARID1A as a novel tumor-suppressor gene in the BE-associated EAC sequence, reiterating the importance of aberrant chromatin in this process.
MATERIALS AND METHODS

Next-generation sequencing
Libraries for NGS were generated using DNA obtained from archived snapfrozen endoscopic mucosal biopsies from a treatment-naive 51-year-old Caucasian male with a pT2NxMx EAC. Libraries were prepared from three independent samples obtained during upper endoscopy: NSE (germ line control), BE and EAC. Reference samples were taken directly adjacent to where the research biopsies had been obtained. Two expert gastrointestinal pathologists (EAM and AM) confirmed that the lesion biopsies 
40
, this paper An overview of prevalent mutations in EAC identified using NGS by Agrawal et al. 40 and our group. In total, 12 EAC and matched NSE tissue samples were utilized for NGS. Genes in which nonsense and indel mutations were detected in at least 2/12 (16.7%) patients as well as genes in which missense or splice site mutations occurred in 43 cases (25%) are listed in this table. Abbreviations: ARID1A, AT-rich interactive domain 1A (SWI like); EAC, esophageal adenocarcinoma; NGS, next-generation sequencing; NSE, normal squamous epithelium of the esophagus. a CLASP1 mutation was found in only one patient.
ARID1A in
and contained a cellularity of 480%. Total DNA was extracted from the frozen biopsies using the DNeasy kit (Qiagen, Germantown, MD, USA) according to the manufacturer's manual. The patient subsequently received neoadjuvant chemo-radiation therapy, and underwent surgical resection, which demonstrated residual foci of moderately differentiated EAC. He remains disease-free 3 years following the index biopsies.
Library preparation NGS
One milligram of genomic DNA was fragmented using Covaris S2 (Caliper Inc., Waltham, MA, USA). Sequencing libraries were constructed using the NEBNext DNA library preparation kit (New England Biolabs, Ipswich, MA, USA) according to the manufacturer's instructions. DNA was size-selected to an average size of 560 bp, which corresponds to an average insert size of 300 bp. Libraries were quantified on an Agilent bioanalyzer (Agilent, Santa Clara, CA, USA) using a DNA 1000 chip, and sequencing flow cells were prepared using a CBot (Illumina Inc., San Diego, CA, USA). NGS was performed on Illumina HiSeq 2000 (paired-end 100-bp runs) and on Illumina GAIIX (paired-end 150-bp runs).
Alignment
Illumina paired-end reads (ranging from 101 to 151 bp) of EAC, BE and NSE were aligned separately to the human NCBI Build 37 reference sequence using Novoalign software (www.novocraft.com). The aligned sequence files were sorted and merged using SAMtools. 55, 56 Picard (http:// picard.sourceforge.net) was used to remove PCR duplicates from merged bam files. The average genome coverage for EAC, BE and NSE samples were estimated to be 56.2X, 50.3X and 37.9X, respectively. GATK was used for base quality score recalibration, and SNV discovery across was performed for all three samples. 57 Relaxed filtering parameters (clusterWindowSize 10 clusterSize 3 min confidence score filter of 50) were used to label the SNVs as high or low confidence.
Identification of SNVs in EAC and BE
For initial SNV calling, minimal filtering for quality was used to capture as many variants as possible at the initial stage. More subsequent filtering and validation was done, as described below, on the SNVs annotated in or near coding regions. Using GATK, 4090303 SNVs in the EAC, and 4072159 SNVs in the BE tissue were identified. As tissue samples are heterogeneous, relaxed GATK filters were used to minimize the number of false negatives. Subsequently, the SNVs were filtered by comparing the SNVs detected in BE and EAC with those identified in NSE. A total of 3 913 704 of the EAC SNVs and 3 904 615 of the BE SNVs were also detected in the NSE sample, suggesting that these are the patient's inherited SNVs. The remaining 176 599 EAC SNVs and 167 544 BE SNVs were annotated using SeattleSeq (http://snp.gs.washington.edu/SeattleSeqAnnotation131/, accessed on 19 July 2011). 7280 EAC-specific SNVs and 6566 BE-specific SNVs were located in the coding sequences of genes (missense, nonsense, splice3 and splice5), in regulatory regions (UTR3, UTR5, near gene 3 (2 kbp or less upstream of coding sequences), or near gene 5 (2 kbp or less downstream of coding sequences)), and these SNVs were subjected to further manual review.
Comparison of EAC and BE SNVs
In order to identify mutations that are unique to EAC or BE or are shared between these lesions, the lists of EAC and BE SNVs were compared. An in-house Perl script was used to inspect the coding, splice site and regulatory SNVs, and to classify the SNVs into EAC-specific, BE-specific and shared somatic SNVs. Subsequently, the minor allele frequency (MAF) was calculated for every SNV location in each of the three samples using an inhouse Perl script. The detailed comparison strategy is depicted as a flowchart ( Figure 5 ).
The SNVs that met the following criteria were selected as candidate SNVs and validated by Sanger sequencing:
(1) The SNVs have a coverage of Z10 Â in NSE, BE and EAC. ; SNVs located in coding regions of annotated exons and splice sites (tier 1), in conserved genomic regions (tier 2), in non-repeat masked, non-regulatory regions (tier 3) and unclassified SNVs (tier 4).
Sanger sequencing
Tier 1 SNVs and selected tier 2/3/4 SNVs were validated using Sanger sequencing. Primers were designed to amplify the SNV sites using Primer3 (Supplementary Table S8) . 58 Specific PCR conditions are available on request. Sanger sequencing was performed using the PCR primers and the Big Dye terminator sequencing kit (Life Technologies, Grand Island, NY, USA) on an Applied Biosystem 3730XL DNA sequencer (Applied Biosystems, Carlsbad, CA, USA).
Pathway analysis
Tier 1 genes were used as input data for the Ingenuity pathway analysis software (http://www.ingenuity.com) (analysis settings available on request). Six networks were identified, and merged. Figure 5 . A flowchart depicting the comparison strategy to identify EAC-specific, BE-specific and shared SNVs.
ARID1A mutational analysis HGD/EAC and matched NSE frozen biopsies from 15 patients were obtained during upper endoscopy under a Johns Hopkins IRB-approved protocol. In addition, formalin-fixed paraffin-embedded EAC and matched tumor-negative lymph node tissue from five EAC patients were acquired during surgical resection at the University Medical Center in Utrecht. Lesions and normal tissues were manually microdissected, and DNA was extracted using the DNeasy kit (Qiagen). All exons were sequenced using customized primers (Supplementary Table S9 , conditions available on request). Bidirectional Sanger sequencing was performed on an Applied Biosystem 3730XL DNA sequencer.
Immunohistochemical assessment of loss of ARID1A expression in BE progression
In order to validate aberrations of ARID1A protein expression in the multistep progression of EAC, we utilized samples obtained from a relatively large independent cohort of BE patients, which have been engineered into tissue microarrays by our group, as previously described. 59 Briefly, the tissue microarrays included NSE, BE, LGD, HGD, EAC and lymph node metastasis tissues from 98 EAC patients, who had undergone surgical resection of EAC and had not received neoadjuvant chemo-radiation therapy. Patient characteristics including survival time were collected. Pathological features such as histological differentiation grade, presence of metastases and tumor involvement of surgical margins were extracted from the pathological surgical resection reports.
Immunohistochemistry for ARID1A and p53 was performed as previously described by our group. 59 Primary antibodies against ARID1A (HPA005456, dilution 1:100, Sigma Aldrich, St Louis, MO, USA) and p53 (DO-1, dilution 1:400, Santa Cruz, Santa Cruz, CA, USA) were used.
Staining patterns were scored by two authors (MMS and AM). For both ARID1A and p53, nuclear expression was assessed, and categorized in two groups; present and absent accumulation. Using the log-rank test, correlations between ARID1A status and patient outcome were tested. The Student's t-test and w 2 test were run to determine associations between ARID1A status and patient characteristics and tumor features. A P-value o0.05 was considered as statistically significant.
Cell culture and RNA interference
The EAC cell lines OE33 (European Collection of Cell Cultures, Wiltshire, UK) and JHesoAD1, 60 and the human esophageal epithelial cell line HEEpiC (Sciencell, Carlsbad, CA, USA) were grown. OE33 and JHesoAD1 cells were cultured in 1640 RPMI supplemented with 15-20% fetal bovine serum, whereas HEEpiC cells were grown in epithelial cell medium-2 (Sciencell). OE33 cells were transfected using lipofectamine 2000 (Life Technologies) and ON-TARGETplus SMARTpool ARID1A small interfering RNA (50 nM, 48-h incubation, Thermo Fisher Scientific, Lafayette, CO, USA) in order to knockdown ARID1A transcripts. ON-TARGETplus Non-targeting Pool small interfering RNA (Thermo Fisher Scientific) was used for mock transfection.
Western blotting ARID1A expression was validated at protein level by western blot analysis in ARID1A KD OE33, mock OE33, non-transfected OE33, JHesoAD1 and HEEpiC cells. Western blot analysis was performed as previously described by our group. 59 Primary antibodies against ARID1A (A301-041A, Bethyl Laboratories, Montgomery, TX, USA, dilution 1:500) and a-tubulin (protein loading control, Santa Cruz, dilution 1:30 000) were used. Band intensities were measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Cell growth, migration and invasion assays MTT assays were performed to evaluate whether ARID1A KD cells have a growth advantage compared with mock OE33 cells. Migration and invasion assays were performed as previously described. 61 Five randomly selected 20 Â fields were counted per insert, and experiments were performed in triplicate and repeated three times.
Proliferation assay
Proliferation was examined in two biological replicated experiments. OE33 cells were seeded and transfected in cell culture chamber slides (BD Biosciences, San Jose, CA, USA). After 36 h, media was replaced by media containing BrdU. Twelve hours thereafter, BrdU was detected using the BrdU staining kit (Life Technologies). Five random 20 Â fields per experiment were examined. Staining intensity was categorized as follows; moderate-intense, and no-light. Percentages of moderate-intense staining were calculated. A parallel ARID1A immunocytochemistry experiment was performed to confirm ARID1A KD.
Soft agar colony formation assay
Non-transfected, mock and ARID1A KD OE33 cells, mixed in 0.5% agarose in normal growth media, were seeded on a 1% agarose layer. The experiments were performed in triplicate. Colonies were formed after 2 weeks, and were subsequently stained and fixed in 0.005% crystal violet/10% methanol. Colonies were manually counted, and the experiment was repeated twice.
Analysis functional assays
Cell/colony counts were corrected for viability differences by performing a parallel MTT assay. The Mann-Whitney U-test was used to determine statistically significant differences between ARID1A KD and mock OE33 cells.
Identification of ARID1A effector genes Gene expression levels in ARID1A KD were compared with those in mock OE33 cells to identify downstream targets of ARID1A by performing an Affymetrix Human PrimeView Gene Expression Array across two biological replicates. Data were robust micro-array average (RMA) normalized and converted to Log2 notation with Partek Genomics Suite. ARID1A KD and mock experiments were compared with one-way analysis of variance. Potential downstream genes of ARID1A were selected for quantitative reverse transcriptase-PCR validation using the following criteria:
1. An average relative fold change 41.75 in ARID1A KD compared with mock OE33 cells was calculated. 2. The aberrantly expressed gene has a known function in cancer cell proliferation and/or invasion. Available databases of gene function including Ingenuity pathway analysis and Pubmed were queried to identify putative candidate genes that have the ability to control cell proliferation, and/or invasion.
The microarray data are accessible through GEO Series accession number GSE38380 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE38380).
Quantitative real-time PCR RNA was extracted using the RNeasy kit (Qiagen). Quantitative reverse transcriptase-PCR was carried out using SYBR-green reagents (Applied Biosystems) and customized primers (Supplementary Table S10 ). Gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase expression. Relative gene expression levels were calculated using the 2 À DDCT method. 62 Differences between ARID1A KD and mock OE33 cells were tested using the Mann-Whitney U-test. Po0.05 was considered as statistically significant.
